Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
[HTML][HTML] Current pharmacological treatment of hepatocellular carcinoma
S Muñoz-Martínez, G Iserte… - Current Opinion in …, 2021 - Elsevier
The landscape of hepatocellular carcinoma (HCC) has changed since the incorporation of
sorafenib in 2007 as the first pharmacological treatment for HCC. The combination of …
sorafenib in 2007 as the first pharmacological treatment for HCC. The combination of …
Systemic therapies in hepatocellular carcinoma: A revolution?
M Fortuny, M Sanduzzi‐Zamparelli… - United European …, 2024 - Wiley Online Library
The evolution in systemic therapies in hepatocellular carcinoma (HCC) signifies a strategy of
high‐cost, high‐gain innovation that originated with sorafenib, despite its limited impact on …
high‐cost, high‐gain innovation that originated with sorafenib, despite its limited impact on …
Synergistic effects of α-Mangostin and sorafenib in hepatocellular carcinoma: New insights into α-mangostin cytotoxicity
T Wang, Y Hong, ZH Chen, DH Wu, Y Li, X Wu… - Biochemical and …, 2021 - Elsevier
Sorafenib remains the standard first-line treatment for advanced hepatocellular carcinoma
(HCC), although other clinical trials are currently underway for treatments that show better …
(HCC), although other clinical trials are currently underway for treatments that show better …
Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib
V Sapena, M Iavarone, L Boix… - World Journal of …, 2022 - pmc.ncbi.nlm.nih.gov
BACKGROUND Dermatologic adverse events (DAEs) are associated with a better outcome
in patients with hepatocellular carcinoma (HCC) irrespective of the therapeutic agent …
in patients with hepatocellular carcinoma (HCC) irrespective of the therapeutic agent …
[معلومات الإصدار][C] 槐耳颗粒与索拉非尼联用对原发性肝癌术后复发患者的作用效果及对甲胎蛋白, 甲胎蛋白异质体-L3 水**的影响
**大志 - **药物经济学, 2022